Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
zhenfeng, zhang
NCT06478108: Interventional Software for Multi-immunotherapy of Solid Tumors	Recruiting	2/3	60	RoW	IRSW-MIM	Second Affiliated Hospital of Guangzhou Medical University, Immuno (Guangzhou) Biomedicine S&T Ltd	Lung Cancer, Liver Cancer, Solid Tumor, Adult	12/28	12/33
NCT06483347: Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT	Recruiting	2	90	RoW	ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab, Local ICIs.	Second Affiliated Hospital of Guangzhou Medical University	Lung Cancer, Inoperable Disease	12/28	12/33
NCT06195384: Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors	Recruiting	1	30	RoW	Neoantigen mRNA Vaccine	Second Affiliated Hospital of Guangzhou Medical University	Solid Tumor, Adult	12/27	12/37
NCT05341492: EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer	Recruiting	1	30	RoW	EGFR/B7H3 CAR-T	Second Affiliated Hospital of Guangzhou Medical University	EGFR/ B7H3-positive Advanced Lung Cancer, EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer	05/30	05/35
NCT03769129: Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC	Recruiting	N/A	100	RoW	Pembrolizumab, Keytruda, microwave ablation	Second Affiliated Hospital of Guangzhou Medical University	Non Small Cell Lung Cancer	11/26	11/29